SR-9009
Stenabolic · Rev-erb agonist (unapproved)
What it is
A circadian-biology research tool (Rev-erb agonist) from Scripps that showed increased mitochondrial activity and exercise capacity in mice, marketed since as "exercise in a bottle."
What human evidence shows
Mouse data only. The foundational exercise studies used injected administration in mice; human pharmacokinetics and oral exposure are not established, and some of its cellular effects occur independently of Rev-erb — the mechanism story is less clean than marketed. No human trials exist.
Risks
Unknown by absence of study, which is not the same as safe. Perturbing circadian clock machinery is a systemic intervention, not a targeted one. WADA bans it.
Legal status
US: not FDA-approved for human use; unscheduled. Marketing for human use may violate the FD&C Act.
Evidence base
substantial literature
Studied, but no human trial report found. A real literature that is preclinical as far as these counts can see.
- phase 3/4
- 0
- randomised
- 0
- reviews
- 0
- human trials
- 0
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Research (12)
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsNature · 2012
- Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feedingNat Commun · 2021
- REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axisNat Commun · 2018
- NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING SignalingCancer Res · 2023
- Rhythms under tension: Circadian clocks in an Unsynced SocietyBiomed J · 2025
- The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasomeJ Neuroinflammation · 2022
- BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissectionCardiovasc Res · 2026
- New biochemical approaches for the treatment of glioblastomaJ Biol Chem · 2025
- Nobiletin promotes lipolysis of white adipose tissue in a circadian clock-dependent mannerJ Nutr Biochem · 2024
- SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBsCell Death Dis · 2022
- Rev-erbα agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathwayFront Pharmacol · 2023
- SR9009 improves heart function after pressure overload independent of cardiac REV-ERBFront Cardiovasc Med · 2022
Turn SR-9009 into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included